Idifarma has begun its seventh project with Spanish biotechnology company, Palobiofarma. Under the terms of the agreement, Idifarma will handle the full pharmaceutical development of Palobiofarma’s new development candidate, the compound  PBF-2897. This will include drug formulation, development of analytical methods and GMP manufacturing for clinical trials from its EU GMP facility in Pamplona, Spain. PBF-2897 represents a novel co-crystal form of PBF-680, which is a potent, non-BB...